1. Search Result
Search Result
Results for "

antitumor efficacy

" in MedChemExpress (MCE) Product Catalog:

225

Inhibitors & Agonists

6

Peptides

2

Inhibitory Antibodies

18

Natural
Products

3

Isotope-Labeled Compounds

4

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161078

    Amyloid-β Cancer
    QP5038 (compound 28) is an inhibitor of QPCTL with an IC50 value of 3.8 nM. QP5038 has antitumor efficacy .
    QP5038
  • HY-130115

    STING Cancer
    IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .
    IACS-8803
  • HY-164484

    Raf Cancer
    IHMT-RAF-128, a highly potent pan-RAF inhibitor. IHMT-RAF-128 shows potent antitumor efficacy in xenograft mouse tumor models without causing any apparent toxicities .
    IHMT-RAF-128
  • HY-155647

    Microtubule/Tubulin Cancer
    Microtubule stabilizing agent-1 (compound 3l) is a Paclitaxel derivative that efficiently promotes tubulin polymerization. Microtubule stabilizing agent-1 shows antitumor efficacy .
    Microtubule stabilizing agent-1
  • HY-146034

    NOD-like Receptor (NLR) Inflammation/Immunology Cancer
    NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC50 values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) .
    NOD1/2 antagonist-1
  • HY-147695

    c-Met/HGFR Cancer
    c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC50 of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .
    c-Met-IN-12
  • HY-121349

    Bacterial Fungal Antibiotic Infection Cancer
    Aerothionin is an antibiotic with potent antimicrobial efficacy against bacteria and fungi. Aerothionin exhibits antitumor efficacy against adrenal pheochromocytomas and extra-adrenal paragangliomas (PPGLs) .
    Aerothionin
  • HY-130116

    STING Cancer
    IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy .
    IACS-8779
  • HY-161077

    Amyloid-β Cancer
    QP5020 (compound 28) is an inhibitor of QPCTL with an IC 50 value of 15 nM. QP5020 has antitumor efficacy .
    QP5020
  • HY-162449

    Apoptosis Ferroptosis Cancer
    GIC-20 is a dual inducer for apoptosis and ferroptosis. GIC-20 exhibits antitumor efficacy against fibrosarcoma .
    GIC-20
  • HY-115833

    Others Cancer
    Histamine H4 receptor antagonist-2 serves as a potent activator of p53, demonstrating significant antitumor efficacy.
    Histamine H4 receptor antagonist-2
  • HY-157302

    c-Met/HGFR Cancer
    c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC50 value of 0.45? nM, and shows anti-tumor efficacy in vivo .
    c-Met-IN-21
  • HY-130115A
    IACS-8803 disodium
    1 Publications Verification

    STING Cancer
    IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy .
    IACS-8803 disodium
  • HY-130115B
    IACS-8803 diammonium
    1 Publications Verification

    STING Cancer
    IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy .
    IACS-8803 diammonium
  • HY-155020

    Histone Methyltransferase GLP Receptor Cancer
    Antitumor agent-101 is a selective covalent inhibitor of lysine methyltransferases G9a/GLP, with IC50s of 8.5 nM and 5.5 nM for G9a and GLP, respectively. Antitumor agent-101 shows antitumor efficacy in the PANC-1 xenograft model .
    Antitumor agent-101
  • HY-100510
    RAF709
    5+ Cited Publications

    Raf Cancer
    RAF709 is a potent, selective, and efficacious RAF inhibitor with IC50s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively . Antitumor efficacy .
    RAF709
  • HY-133117A

    IKK Cancer
    (Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective TBK1 inhibitor with an IC50 of 1.5 nM. Antitumor efficacy .
    (Rac)-BAY-985
  • HY-150256

    YAP Cancer
    YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC50 of 4 nM. YTP-17 shows anti-tumor efficacy .
    YTP-17
  • HY-101096

    MK-8998; CX-8998; JZP385

    Calcium Channel Neurological Disease Cancer
    Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth .
    Suvecaltamide
  • HY-162085

    TAM Receptor Cancer
    Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .
    Axl-IN-17
  • HY-P10255

    Potassium Channel Cancer
    K90-114TAT is an inhibitor for EAG2-Kvβ2 interaction, and exhibits antitumor efficacy against glioblastomas .
    K90-114TAT
  • HY-164386

    OM 174

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Defoslimod (OM 174) is an agonist for TLR4 receptor and acts as an immunomodulator. Defoslimod activates macrophages and dendritic cells, induces cytokines secretion, and exhibits antitumor efficacy in rats .
    Defoslimod
  • HY-153831

    c-Met/HGFR Cancer
    c-Met-IN-17 is a potent c-Met kinase inhibitor with an IC50 of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    c-Met-IN-17
  • HY-163768

    β-catenin Inflammation/Immunology Cancer
    Antitumor agent-172 (Compound 28) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 3.92 μM. Antitumor agent-172 exhibits high affinity to β-catenin with Kd of 82 nM. Antitumor agent-172 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
    Antitumor agent-172
  • HY-155146

    Necroptosis Cancer
    Anticancer agent 146 (compound 1.19) is a necroptosis inducer. Anticancer agent 146 has anti-tumor efficacy in the mouse MDA-MB-231 xenograft model .
    Anticancer agent 146
  • HY-120885

    Ras Cancer
    (+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy .
    (+)-Oxanthromicin
  • HY-138799A

    HDAC Inflammation/Immunology Cancer
    KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects .
    KA2507 monohydrochloride
  • HY-130116A

    STING Cancer
    IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .
    IACS-8779 disodium
  • HY-116447

    Mitochondrial Metabolism Apoptosis Cancer
    Antitumor agent-159 (Compound 13b) targets the mitochondria and downregulates cardiolipin levels. Antitumor agent-159 inhibits the proliferation of cancer cell MDA-MB-231, arrests the cell cycle at sub-G1 phase, and induces apoptosis in MDA-MB-231. Antitumor agent-159 exhibits antitumor efficacy in MDA-MB-231 xenograft mouse models .
    Antitumor agent-159
  • HY-147136

    Others Cancer
    MYF-03-176 is an orally active and potent anticancer agent. MYF-03-176 shows strong antitumor efficacy in MPM mouse xenograft model via oral administration .
    MYF-03-176
  • HY-146231

    PROTACs MAP4K Inflammation/Immunology Cancer
    SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy .
    SS47
  • HY-115690

    Others Cancer
    K-TMZ is a derivative of methyl ketone, which exhibits antitumor efficacy against O 6 -methylguanine DNA methyltransferase (MGMT) deficient cell. K-TMZ can be used for research of glioblastoma .
    K-TMZ
  • HY-13646C

    HM30181 mesylate hydrochloride; HM30181A mesylate hydrochloride

    P-glycoprotein Cancer
    Encequidar (HM30181) mesylate hydrochloride is a potent and selective inhibitor of P-glycoprotein (MDR1). Encequidar mesylate hydrochloride improves anti-tumor efficacy of Paclitaxel (HY-B0015) in mouse tumor models .
    Encequidar mesylate hydrochloride
  • HY-13636S

    ICI 182780-d3; ZD 9238-d3; ZM 182780-d3

    Isotope-Labeled Compounds Estrogen Receptor/ERR Autophagy Apoptosis Cancer
    Fulvestrant-d3 is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].
    Fulvestrant-d3
  • HY-163766

    Estrogen Receptor/ERR Cancer
    Antiproliferative agent-51 (Compound 18h) exhibits inhibitory efficacy against estrogen receptor α (ERα) mediated transcription, with an IC50 of 1.6 nM. Antiproliferative agent-51 inhibits the proliferation of cancer cell ZR-75, with an IC50 of 0.031 μM. Antiproliferative agent-51 exhibits antitumor efficacy in mouse models .
    Antiproliferative agent-51
  • HY-W402682

    Others Neurological Disease Cancer
    SXC2023 is an inhibitor for solute carrier family 7 member 11 (SLC7A11). SXC2023 exhibits antitumor efficacy, and ameliorates central nervous system disorder through downregulation of glutamate export .
    SXC2023
  • HY-145688

    HDAC Cancer
    HDAC-IN-33 is a potent HDAC inhibitor with IC50s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity .
    HDAC-IN-33
  • HY-149717

    Others Cancer
    Antitumor agent-122 (Compound 5j) is an antitumor agent with good efficacy, limited toxicity and low resistance. Antitumor agent-122 has antiproliferative activity for MGC-803 cell, HepG2 cell, SKOV3 cell and T24 cell with IC50 values of 5.23 μM, 3.60 μM, 1.43 μM, 3.03 μM, respectively .
    Antitumor agent-122
  • HY-146465

    Microtubule/Tubulin Cancer
    Anticancer agent 60 (compound 3h) has antiproliferative activity against human HepG2 cells (IC50 = 4.13 μM) and presents antitumor efficacy in a human HepG2 xenograft mouse model .
    Anticancer agent 60
  • HY-162396

    P-glycoprotein Cancer
    P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .
    P-gp inhibitor 21
  • HY-128222

    Hydrazinecarboselenoamide

    Bacterial Infection Cancer
    Selenosemicarbazide (Hydrazinecarboselenoamide) exhibits antimicrobial activity, that inhibits B. subtilis, S. aureus, Klebsiella pneumoniae, Sarcina lutea and Mycobacterium tuberculosis. Selenosemicarbazide forms complex with metal ions, and exhibits antitumor efficacy against cancer cells
    Selenosemicarbazide
  • HY-145687

    HDAC Cancer
    HDAC-IN-32 is a potent HDAC inhibitor with IC50s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity .
    HDAC-IN-32
  • HY-151292

    DNA/RNA Synthesis Cancer
    Antitumor agent-74 (compound 13da) is a quinoxalines derivative, an antitumor agent. Antitumor agent-74 exhibits more potent efficacy on tumor inhibition, mixed with regioisomer Antitumor agent-75 (HY-151295, compound 14 da) (mriBIQ 13da/14da). mriBIQ 13da/14da attests cell cycle at S phase, inhibits DNA synthesis, and induces mithochondrial apoptosis .
    Antitumor agent-74
  • HY-158649

    Fatty Acid Synthase (FASN) Apoptosis Cancer
    Fasnall benzenesulfonate is the benzenesulfonate salt form of Fasnall (HY-121250). Fasnall benzenesulfonate is the inhibitor for fatty acid synthase (FASN) with IC50 of 3.7 μM. Fasnall benzenesulfonate inhibits the proliferation and induces apoptosis in breast cancer cells. Fasnall benzenesulfonate exhibits antitumor efficacy in mice .
    Fasnall benzenesulfonate
  • HY-162644

    PD-1/PD-L1 PARP Cancer
    Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC50 of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a Ki of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics .
    Antitumor agent-170
  • HY-N8342

    VEGFR Inflammation/Immunology Cancer
    Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .
    Rhamnazin
  • HY-163767

    β-catenin Inflammation/Immunology Cancer
    Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with Kd of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC50 of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC50 of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
    Antitumor agent-171
  • HY-10080

    GMX1777; EB-1627

    NAMPT Cancer
    Teglarinad chloride (GMX1777) is a proagent of GMX1778 (a nicotinamide phosphoribosyl transferase inhibitor). Teglarinad chloride exhibits antitumor activity in mice can be attributed to inhibition of NAMPT. Teglarinad chloride also enhances radiation efficacy, mediated by interference with DNA repair and antiangiogenesis .
    Teglarinad chloride
  • HY-130628

    PAK Cancer
    PAK4-IN-1 (Compound 19) is a potent, selective, orally active PAK4 inhibitor with robust anti-tumor efficacy in vivo. PAK4-IN-1 is stable under both acidic and neutral conditions .
    PAK4-IN-1
  • HY-146397

    PROTACs Androgen Receptor Cancer
    TD-802 (Compound 33c) is an androgen receptor (AR) PROTAC degrader with good microsomal stability. TD-802 has good antitumor efficacy in vivo and can be used for metastatic castration-resistant prostate cancer research .
    TD-802

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: